United States · Wires & real time · PR Newswire

Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology

Published by PR Newswire · United States 1 h ago

- Grants Astellas exclusive option to obtain worldwide license to develop and commercialize DAX-044, with Audax having the option to co-fund and co-promote DAX-044 in Australia…

Read the full article on PR Newswire Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)

Also worth reading

Business Wire

Peoples Security Bank & Trust Welcomes Scott Campagna as Executive Vice President, Chief Information Officer

Associated Press (Business)

Baby orangutans in India expose illegal wildlife trade as experts question a billionaire’s zoo

Dow Jones Newswires

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

MT Newswires

Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology

Share

Also worth reading

Peoples Security Bank & Trust Welcomes Scott Campagna as Executive Vice President, Chief Information Officer

Baby orangutans in India expose illegal wildlife trade as experts question a billionaire’s zoo

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows